Table 2.
Pharmacokinetic parameters of anidulafungin after intraperitoneal administration of various doses of AFGa
| Dose (mg/kg) | AUC0–24 (mg · h/liter) | Dose-normalized AUC [(mg · h)/(liter · kg)] | Tmax (h) | Cmax (mg/liter) | Cmin (mg/liter) | CLss/F [liter/(h · kg)] | t1/2 (h) |
|---|---|---|---|---|---|---|---|
| 2.5 | 46.5b | 18.6b | |||||
| 5 | 93 | 18.6 | 8 | 7.9 | 0.82 | 0.05 | 17.3448 |
| 10 | 141.4 | 14.1 | 2 | 10.7 | 3.3 | 0.07 | 17.3849 |
| 20 | 326.3 | 16.3 | 0.5 | 22.2 | 6.4 | 0.06 | 22.7847 |
| 40 | 802.7 | 20.1 | 4 | 49.5 | 20.7 | 0.05 | 15.3336 |
a
AFG doses of 2.5 to 40 mg/kg were used. Intraperitoneal therapy was begun at 24 h postinfection with standard daily dosing of AFG, in addition to a single loading dose of AFG. Tmax, time to Cmax; Cmin, minimum concentration in plasma; CLss/F, apparent steady-state clearance; t1/2, half-life.
b
Simulated analysis of pharmacokinetic assay with concentrations ranging from 5 to 40 mg/kg.